Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

Morepen launches Empamore for diabetes care with affordable treatment

Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure

Philips and Medtronic partner to upskill 300+ clinicians in structural heart imaging in India

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

Need for inter-sectoral collaboration, enhanced research, and innovative practices to address growing burden of NCDs: Health Secretary Srivastava

The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

The trademark rights for these brands will be transferred to Lupin by March next year.

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate